GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ARIAD Pharmaceuticals Inc (NAS:ARIA) » Definitions » Cyclically Adjusted PB Ratio

ARIAD Pharmaceuticals (ARIAD Pharmaceuticals) Cyclically Adjusted PB Ratio : (As of May. 05, 2024)


View and export this data going back to 1994. Start your Free Trial

What is ARIAD Pharmaceuticals Cyclically Adjusted PB Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


ARIAD Pharmaceuticals Cyclically Adjusted PB Ratio Historical Data

The historical data trend for ARIAD Pharmaceuticals's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ARIAD Pharmaceuticals Cyclically Adjusted PB Ratio Chart

ARIAD Pharmaceuticals Annual Data
Trend Dec06 Dec07 Dec08 Dec09 Dec10 Dec11 Dec12 Dec13 Dec14 Dec15
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

ARIAD Pharmaceuticals Quarterly Data
Dec11 Mar12 Jun12 Sep12 Dec12 Mar13 Jun13 Sep13 Dec13 Mar14 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of ARIAD Pharmaceuticals's Cyclically Adjusted PB Ratio

For the Biotechnology subindustry, ARIAD Pharmaceuticals's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


ARIAD Pharmaceuticals's Cyclically Adjusted PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, ARIAD Pharmaceuticals's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where ARIAD Pharmaceuticals's Cyclically Adjusted PB Ratio falls into.



ARIAD Pharmaceuticals Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

ARIAD Pharmaceuticals's Cyclically Adjusted Book per Share for the quarter that ended in Sep. 2016 is calculated as:

For example, ARIAD Pharmaceuticals's adjusted Book Value per Share data for the three months ended in Sep. 2016 was:

Adj_Book=Book Value per Share/CPI of Sep. 2016 (Change)*Current CPI (Sep. 2016)
=-0.239/101.8610*101.8610
=-0.239

Current CPI (Sep. 2016) = 101.8610.

ARIAD Pharmaceuticals Quarterly Data

Book Value per Share CPI Adj_Book
200612 0.463 85.142 0.554
200703 0.424 86.640 0.498
200706 0.216 87.906 0.250
200709 0.090 87.964 0.104
200712 -0.114 88.616 -0.131
200803 -0.339 90.090 -0.383
200806 -0.564 92.320 -0.622
200809 -0.828 92.307 -0.914
200812 -0.995 88.697 -1.143
200903 -0.794 89.744 -0.901
200906 -1.017 91.003 -1.138
200909 -0.664 91.120 -0.742
200912 -0.816 91.111 -0.912
201003 -1.012 91.821 -1.123
201006 0.494 91.962 0.547
201009 0.321 92.162 0.355
201012 0.505 92.474 0.556
201103 0.396 94.283 0.428
201106 0.060 95.235 0.064
201109 0.202 95.727 0.215
201112 1.397 95.213 1.495
201203 1.555 96.783 1.637
201206 1.273 96.819 1.339
201209 0.989 97.633 1.032
201212 0.675 96.871 0.710
201303 1.972 98.209 2.045
201306 1.676 98.518 1.733
201309 1.367 98.790 1.409
201312 0.998 98.326 1.034
201403 0.778 99.695 0.795
201406 0.657 100.560 0.666
201409 0.433 100.428 0.439
201412 0.431 99.070 0.443
201503 0.202 99.621 0.207
201506 -0.073 100.684 -0.074
201509 -0.262 100.392 -0.266
201512 -0.544 99.792 -0.555
201603 -0.806 100.470 -0.817
201606 -0.197 101.688 -0.197
201609 -0.239 101.861 -0.239

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


ARIAD Pharmaceuticals  (NAS:ARIA) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


ARIAD Pharmaceuticals Cyclically Adjusted PB Ratio Related Terms

Thank you for viewing the detailed overview of ARIAD Pharmaceuticals's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


ARIAD Pharmaceuticals (ARIAD Pharmaceuticals) Business Description

Traded in Other Exchanges
N/A
Address
ARIAD Pharmaceuticals Inc was organized as a Delaware corporation in April 1991. It is an oncology company. The Company is focused on discovery and development of breakthrough medicines to treat cancers by regulating cell signaling with small molecules. The Company's first approved cancer medicine, Iclusig (ponatinib), and its product candidates, AP26113 and ridaforolimus, were discovered internally by its scientists based on the expertise in computational and structure-based drug design. AP26113 is an investigational inhibitor of anaplastic lymphoma kinase, or ALK. In non-clinical studies, AP26113 also demonstrated that it can inhibit epidermal growth factor receptor, or EGFR, and c-ros oncogene-1, or ROS1. . Iclusig and its drug candidates and preclinical compounds are small molecules that can be readily synthesized by processes that it has developed. The Company do not own or operate manufacturing facilities for the production of clinical or commercial quantities of Iclusig or its product candidates. The company's competitors includes pharmaceutical and biotechnology companies such as Amgen Inc., AstraZeneca PLC, Bristol-Myers Squibb Company, Celgene Corporation, Eli Lilly and Company, the Roche Group, GlaxoSmithKline plc, Johnson & Johnson, Merck, Merck KGaA, Novartis AG, Pfizer, Inc., Sanofi-Aventis, Takeda Pharmaceutical Co., Ltd., and Teva Pharmaceutical Industries Ltd.Inc.
Executives
Alexander J Denner director C/O SARISSA CAPITAL MANAGEMENT LP, 660 STEAMBOAT ROAD, 3RD FLOOR, GREENWICH CT 06830
Norbert G Riedel director BAXTER INTERNATIONAL INC, ONE BAXTER PKWY DF2-1W, DEERFIELD IL 60015
Elona Esq. Kogan officer: Sr. V. P. - General Counsel C/O SEER, INC., 3800 BRIDGE PARKWAY, SUITE 102, REDWOOD CITY CA 94065
Manmeet Singh Soni officer: EVP, CFO & Treasurer C/O PHARMACYCLICS, INC., 995 EAST ARQUES AVE, SUNNYVALE CA 94085
Timothy P Clackson officer: President, R&D, CSO C/O ARIAD PHARMACEUTICALS INC, 26 LANDSDOWNE STREET, CAMBRIDGE MA 02139
Jules Haimovitz director 601 108TH AVENUE NE, SUITE 1200, BELLEVUE WA 98004
Daniel M Bollag officer: Sr. VP, Reg. Affairs & Quality C/O ARIAD PHARMACEUTICALS, INC., 26 LANDSDOWNE STREET, CAMBRIDGE MA 02139
Hugh M Cole officer: SVP, Chief Business Officer C/O ARIAD PHARMACEUTICALS, INC, 26 LANDSDOWNE STREET, CAMBRIDGE MA 02139
George Bickerstaff director C/O VION PHARMACEUTICALS, INC., 4 SCIENCE PARK, NEW HAVEN CT 06511
Paris Panayiotopoulos director, officer: President and CEO ARIAD PHARMACEUTICALS, INC., 26 LANDSDOWNE STREET, CAMBRIDGE MA 02139
Anna Protopapas director MILLENNIUM PHARMACEUTICALS, INC., 40 LANDSDOWNE STREET, CAMBRIDGE MA 02139
Sarah J. Schlesinger director C/O ARIAD PHARMACEUTICALS, 26 LANDSDOWNE STREET, CAMBRIDGE MA 02139
Massimo Radaelli director C/O ARIAD PHARMACEUTICALS, INC., 26 LANDSDOWNE STREET, CAMBRIDGE MA 02139
Martin J Duvall officer: EVP, CCO MGI PHARMA, INC., 5775 WEST OLD SHAKOPEE ROAD, SUITE 100, BLOOMINGTON MN 55437
Frank Haluska officer: SVP, Clinical R&D, CMO C/O ARIAD PHARMACEUTICALS, INC., 26 LANDSDOWNE STREET, CAMBRIDGE MA 02139

ARIAD Pharmaceuticals (ARIAD Pharmaceuticals) Headlines

From GuruFocus